Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I will go
SNG
SAV
GDR
Good luck all.
Hard to balance hope v rational thought.
I will go with hope this month.
Sar 5.80
EISB 13.25
Synairgen 193.80
MILA - on todays Sunday roast.
Ok so this is the paper that explains COVIDITY. Already doing very well in academic circles thanks to @Ckeanerworld on the SCLP bb.
Grab yourselves a pot of tea/coffee and some biscuits and enjoy a nice Sunday morning read ;-)
https://www.biorxiv.org/content/10.1101/2021.06.18.448932v1
Sorry posted wrong month thread!
I’ll go
REVB - Revolution Beauty £1.15
Sclp - 21.10p
Redx 62.50p
Many Thanks 1509
I’ll go
REVB - Revolution Beauty £1.15
Sclp - 21.10p
Redx 62.50p
Many Thanks 1509
1509,
Will go with
Lys. 1.77€
Brh.
Iqai
Thanks
Thanks 1509.
MILA - heavily undervalued, 28,000Oz, Assays due
COIN - closest thing to metaverse
Regards
ODX - CE Home test RNS due
THG - Recovery play, expected revenue > £2 Billion for 2021, been heavily buying up companies
SNG - Possibility of news re-P3 trial but probs early 2022
Right then so everyone knows which shares to short my predictions are
copl news/recovery
qbt possible update
omi news
BoJo
polx 64 55 -9 -0.140625 -14.0625
sclp 19.75 21.1 1.35 0.06835443 6.835443038
redx 81 62.5 -18.5 -0.228395062 -22.83950617
Brazil
ocugen 6.98 5.76 -1.22 -0.1747851 -17.47851003
ben 20.25 30.5 10.25 0.50617284 50.61728395
qbt 3.55 3.2 -0.35 -0.098591549 -9.85915493
d gee
agl 122 134 12 0.098360656 9.836065574
eve 3 2.75 -0.25 -0.083333333 -8.333333333
sng 198 193.8 -4.2 -0.021212121 -2.121212121
Ihowells
val 50 34.5 -15.5 -0.31 -31
hzm 8.45 6.52 -1.93 -0.228402367 -22.84023669
arcm 3.175 2.6 -0.575 -0.181102362 -18.11023622
John
copl 30.5 19.8 -10.7 -0.350819672 -35.08196721
omi 15.3 11.625 -3.675 -0.240196078 -24.01960784
kuchto 0.86 1.04 0.18 0.209302326 20.93023256
Maf
gcat 1.4 1.24 -0.16 -0.114285714 -11.42857143
orph 20 21 1 0.05 5
matd 2.72 2.8 0.08 0.029411765 2.941176471
Nolupus
brh 30.5 37.5 7 0.229508197 22.95081967
lys 2.09 1.77 -0.32 -0.153110048 -15.31100478
dbv 5.75 4.94 -0.81 -0.140869565 -14.08695652
rise
sng 198 193.8 -4.2 -0.021212121 -2.121212121
fluor grp 19.7 22.45 2.75 0.139593909 13.95939086
valkeva 20.14 23.62 3.48 0.172790467 17.27904667
Vl
mos 0.61 0.4 -0.21 -0.344262295 -34.42622951
gst 3.35 2.37 -0.98 -0.292537313 -29.25373134
avct 116.2 120 3.8 0.032702238 3.270223752
Will
arb 122.5 123 0.5 0.004081633 0.408163265
eqt 1.2 1.36 0.16 0.133333333 13.33333333
dev 30.75 31 0.25 0.008130081 0.81300813
xv
val 50 34.5 -15.5 -0.31 -31
iqai 6.2 6.25 0.05 0.008064516 0.806451613
eisb 14.72 13.25 -1.47 -0.09986413 -9.986413043
1509
odx 49.5 26.5 -23 -0.464646465 -46.46464646
copl 30.5 19.8 -10.7 -0.350819672 -35.08196721
cbx 6.9 7.75 0.85 0.123188406 12.31884058
Morning
What a month more ups and downs than the big one at Blackpool.
Still waiting to get my mojo back through copl
Well done to everyone
Top 3
Brazil Ben 50.61
Nolupus Brh 22.95
John Kutcho 20.9
special mention to Willibo who managed 3 positive percentages
Full results in next post
board/posting vatigue
or BPV.lol.
Yes researching, investing and holding can become tiring.
I might go with unjustified drop. I will probably buy back in Monday.
Lot of uncertainty. I think I'm going to look away for a bit - I have a good book to read - it might be a good idea to make a few decisions and stick to them for a bit.
This is from the University of Southampton who conducted the trial.
https://www.uhs.nhs.uk/whats-new/press-releases/university-hospital-southampton-led-trial-publishes-covid-19-booster-data
The VLA vaccine is an ‘inactivated’ vaccine. Not necessarily any better or worse, just a case of swings and roundabouts IMO. Seems like an unjustified drop to me but not invested. To be shortlisted as one of the 7 possible boosters shows it must be a recognised vax.
Thank you. I wish I was risen! That all makes lots more sense. I really appreciate the info. I did reduce my holding in Synairgen first thing so that’s bound to go up Monday morning. Let’s hope Valneva stays in the race..exciting times!
sorry that should be riseup!
can't bear that predictive text (it once turned halfbutt into halibut).
Risen
the text I just posted is valneva's response. (minus a bit to make it fit in).
if you subscribe to the press release info on their website they will send you info like this when they have it.
The COV-Boost trial, which launched in May 2021 and was led by University Hospital Southampton NHS Foundation Trust, included Valneva’s inactivated, adjuvanted, whole virus COVID-19 vaccine candidate VLA2001. The aim of the COV-Boost trial was to quickly generate data to inform advice from the UK’s Joint Committee on Vaccination and Immunization on the autumn booster campaign. Participants were given a booster dose relatively early, only two to three months after completion of the second dose of the primary vaccination series, when they did not need a booster from either an immunological standpoint or under the currently recommended interval for licensed COVID-19 vaccines. Valneva believes it is likely that the short interval between the second shot and booster shot could have adversely impacted the results for VLA2001, given that a longer interval is generally required for inactivated vaccines.
The Company has already begun generating data to inform any regulatory discussions regarding a potential booster indication for VLA2001. The first data from a continuation of existing clinical trials (homologous) are expected in the first quarter of 2022. Additionally, Valneva is in the process of setting up a dedicated heterologous booster trial. All of Valneva’s trials will evaluate a booster shot provided at least six months after primary vaccination, as per the currently recommended interval for licensed COVID-19 vaccines. The results of the COV-Boost trial were never intended to be, nor will they be, part of the Company’s regulatory submissions to the UK Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA), which seek approvals for VLA2001 in the primary vaccination context solely based on the positive data from the pivotal Phase 3 Cov-Compare trial.
Juan Carlos Jaramillo, MD, Chief Medical Officer of Valneva, said, “The setting in the study leads us to believe that COV-Boost does not allow any conclusions to be reached regarding the use of VLA2001 as a booster in a real-life setting. The protective antibody threshold has not yet been established therefore relative increases in antibody levels should not be seen as indicative of efficacy. I concur with Professor Faust’s statements that the data describe the immune response at 28 days, not vaccine effectiveness, and that the relationship between that response and long-term protection is still poorly understood, especially since several studies have shown that longer periods between doses improve immune response. Our submissions for authorization of VLA2001 in a primary vaccination context remain on track, with the EMA announcing yesterday that it has started its rolling review of VLA2001, and our teams are working diligently so that we can quickly deploy our vaccine and ensure it reaches the people who need it.”
Is there an RNS or French equivalent?
Xviolet Nolupus
Thank you. I am just going to hang in there. The science remains the same. I still think the government is trying to reduce the impact of the science to come reference the vaccine effectiveness. A Covid booster will of course help but I am guessing a vaccine that is more specific to the mutations will ultimately still be better in the end. Let’s see. Xviolet I will look up those people you mentioned, thank you. Nolupus where have you seen the latest Valneva news I cannot find it in the Valneva site? Thank you both.
Valneva,
Sent out an explanation, let’s see where this will go from here